Despite how common GLP-1 use has become, there has been relatively little dermatology-focused research on their cutaneous side effects, with most of the existing literature limited to individual case reports. For the cross-sectional analysis, researchers compared cutaneous adverse events reported in the FDA Adverse Event Reporting System (FAERS) for the GLP-1 receptor agonists semaglutide (Ozempic/ Wegovy, Novo Nordisk), liraglutide, exenatide and dulaglutide (Trulicity, Eli Lilly) with cutaneous adverse event reports for the dipeptidyl peptidase-4 (DPP-IV) inhibitors sitagliptin, saxagliptin, linagliptin and alogliptin
Frequent injections sometimes four to five times a day can lead to a level of routine and familiarity with the process, shaped by frequent exposure
135 , jcs259666 (2022)
Clinical trials using both myo-inositol and D-chiro-inositol found no serious adverse effects, even after several months of daily use
These types of therapies therefore generally require high doses and long treatment durations, which increase the risk of undesirable side effects
Week 5 to 6: Continue reducing carbohydrates toward the 50-gram range
